CN104189732A - Traditional Chinese medicine composition for treating osteosarcoma - Google Patents
Traditional Chinese medicine composition for treating osteosarcoma Download PDFInfo
- Publication number
- CN104189732A CN104189732A CN201410383151.XA CN201410383151A CN104189732A CN 104189732 A CN104189732 A CN 104189732A CN 201410383151 A CN201410383151 A CN 201410383151A CN 104189732 A CN104189732 A CN 104189732A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- radix
- herba
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating osteosarcoma, which comprises the following raw materials in parts by weight: 30-50 g of radix morindae officinalis, 25-35 g of eupolyphoge sinensis, 140-170 g of long-noded pit viper, 40-55 g of fructus lycii, 5-10 large centipedes, 50-100 g of pangolin, 35-45 g of spreading hedyotis herbs, 90-110 g of astragalus, 10-30 g of cordyceps sinensis, 35-45 g of the bark of eucommia, 25-32 g of christina loosestrife herbs, 15-25 g of rhizoma chuanxiong, 8-12 g of radix aconiti, 8-12 g of olibanum, 8-15 g of myrrh, 0.8-1.2 g of musk, 8-12 g of rhizoma sparganii, 8-12 g of rhizoma zedoariae, 2-4 g of polygala aureocauda dunn, 3-4 g of artemisia annua, 3-5 g of spicate clerodendranthus herbs, and 10-15 g of picris hieracioides. The traditional Chinese medicine composition disclosed by the invention, through scientific compatibility and mutual complementation, has the effects of diminishing swellings, relieving pain, clearing and activating the channels and collaterals, removing putrefaction, promoting the secretion of saliva or body fluid, soothing the nerves, strengthening the body resistance and expelling the evil, dispersing blood stasis, replenishing blood and tonifying the nerves, treats osteosarcoma quickly and efficiently, and has no toxic and side effects.
Description
Technical field
The present invention relates to one and treat osteosarcomatous Chinese medicine composition, belong to the field of Chinese medicines.
Background technology
Osteosarcoma is one the most common in bone malignant tumour, is to develop from Interstitial cell system, and tumor ramp is because tumor directly or indirectly forms tumor osteoid tissue and osseous tissue through the cartilage stage; Loading by lower limbs bone, under the effect of extraneous factor (as virus), makes cell mutation, may form relevant with osteosarcoma; Osteosarcomatous outstanding symptom is the pain of tumor locus, due to tumor tissues etch and dissolving cortical bone; Osteosarcoma is still child and the very high disease of teenager mortality of malignant tumors at present, but early discovery and in time treatment are from having improved to a great extent this sick survival rate.
Summary of the invention
The object of the present invention is to provide one to treat osteosarcomatous Chinese medicine composition.
The present invention adopts following technical scheme to achieve these goals:
Treat osteosarcomatous Chinese medicine composition, the weight portion of its constitutive material is: Radix Morindae Officinalis 30-50g, eupolyphoge sinensis 25-35g, Agkistrodon 140-170g, Fructus Lycii 40-55g, Scolopendra 5-10 bar, Squama Manis 50-100g, Herba Hedyotidis Diffusae 35-45g, Radix Astragali 90-110g, Cordyceps 10-30g, Cortex Eucommiae 35-45g, Herba Lysimachiae 25-32g, Rhizoma Chuanxiong 15-25g, Radix Aconiti 8-12g, Olibanum 8-12g, Myrrha 8-15g, Moschus 0.8-1.2g, Rhizoma Sparganii 8-12g, Rhizoma Curcumae 8-12g, Radix Polygalae fallacis 2-4g, Herba Artemisiae annuae 3-4g, Herba clerodendranthi spicati 3-5g and Fols Picridis fuscipilosae 10-15g.
Treat osteosarcomatous Chinese medicine composition, the weight portion of its constitutive material is: Radix Morindae Officinalis 40g, eupolyphoge sinensis 30g, Agkistrodon 150g, Fructus Lycii 50g, 8 of Scolopendras, Squama Manis 85g, Herba Hedyotidis Diffusae 40g, Radix Astragali 100g, Cordyceps 20g, Cortex Eucommiae 40g, Herba Lysimachiae 30g, Rhizoma Chuanxiong 20g, Radix Aconiti 10g, Olibanum 10g, Myrrha 10g, Moschus 1g, Rhizoma Sparganii 10g, Rhizoma Curcumae 10g, Radix Polygalae fallacis 3g, Herba Artemisiae annuae 3.5g, Herba clerodendranthi spicati 4g and Fols Picridis fuscipilosae 12g.
Radix Polygalae fallacis is Polygalaceae polygala; Herba Artemisiae annuae is the annual herb plant of Compositae artemisia; Herba clerodendranthi spicati is the herb of labiate Herba clerodendranthi spicati; Fols Picridis fuscipilosae is the plant that Compositae Fols Picridis fuscipilosae belongs to.
Consumption and usage: take Chinese medicine composition of the present invention, every day, potion, 30 days was a course for the treatment of, can cure general 4-6 the course for the treatment of.
Beneficial effect of the present invention:
Chinese medicine composition of the present invention by science compatibility, complements each other, and has that detumescence, pain relieving, dredge the meridian passage, putrefaction removing promote the production of body fluid, pacifys that soul determine that soul, righting are got rid of evils, effect of detumescence, the beneficial god that enriches blood, treats osteosarcoma effective fast, without any side effects.
Detailed description of the invention
Embodiment 1: treat osteosarcomatous Chinese medicine composition, the weight portion (g) of its constitutive material is: Radix Morindae Officinalis 40g, eupolyphoge sinensis 30g, Agkistrodon 150g, Fructus Lycii 50g, 8 of Scolopendras, Squama Manis 85g, Herba Hedyotidis Diffusae 40g, Radix Astragali 100g, Cordyceps 20g, Cortex Eucommiae 40g, Herba Lysimachiae 30g, Rhizoma Chuanxiong 20g, Radix Aconiti 10g, Olibanum 10g, Myrrha 10g, Moschus 1g, Rhizoma Sparganii 10g, Rhizoma Curcumae 10g, Radix Polygalae fallacis 3g, Herba Artemisiae annuae 3.5g, Herba clerodendranthi spicati 4g and Fols Picridis fuscipilosae 12g.
Consumption and usage: take Chinese medicine composition of the present invention, every day, potion, 30 days was a course for the treatment of, can cure general 4-6 the course for the treatment of.
Model case:
Case 1: Huang, man, 7 years old, suffering from early stage osteosarcoma, there is swelling in part, affected part, touches lump at limbs pain position, accompany obvious tenderness, with symptoms such as heating, discomfort, weight loss, take Chinese medicine composition of the present invention, every day, potion, serve on after three courses for the treatment of, and symptom is clearly better, swelling is not obvious, continue to take after two courses for the treatment of of Chinese medicine composition of the present invention, without any ill symptoms, cure.
Case 2: Liu, female, 13 years old, suffer from early stage osteosarcoma, edema of lower limbs, lump surface skin temperature increases with Superficial veins and appears, lump surface and near soft tissue can have tenderness in various degree, accompany obvious tenderness, with symptoms such as heating, discomfort, weight loss, take Western medicine repeatedly invalid, after take Chinese medicine composition of the present invention, every day potion, serve on after half a year, symptom disappears entirely, cures, so far not recurrence.
Case 3: Zhang, female, 18 years old, suffers from osteosarcoma half a year, edema of lower limbs pain, limbs pain and cause keep away pain property walk lamely, with symptoms such as heating, vomiting, diarrhoea, after take Chinese medicine composition of the present invention, every day, potion, serve on after four courses for the treatment of, cured, and conditions of patients is stable.
Claims (2)
1. the osteosarcomatous Chinese medicine composition for the treatment of, the weight portion that it is characterized in that its constitutive material is: Radix Morindae Officinalis 30-50g, eupolyphoge sinensis 25-35g, Agkistrodon 140-170g, Fructus Lycii 40-55g, Scolopendra 5-10 bar, Squama Manis 50-100g, Herba Hedyotidis Diffusae 35-45g, Radix Astragali 90-110g, Cordyceps 10-30g, Cortex Eucommiae 35-45g, Herba Lysimachiae 25-32g, Rhizoma Chuanxiong 15-25g, Radix Aconiti 8-12g, Olibanum 8-12g, Myrrha 8-15g, Moschus 0.8-1.2g, Rhizoma Sparganii 8-12g, Rhizoma Curcumae 8-12g, Radix Polygalae fallacis 2-4g, Herba Artemisiae annuae 3-4g, Herba clerodendranthi spicati 3-5g and Fols Picridis fuscipilosae 10-15g.
2. the osteosarcomatous Chinese medicine composition for the treatment of according to claim 1, is characterized in that the weight portion of its constitutive material is: Radix Morindae Officinalis 40g, eupolyphoge sinensis 30g, Agkistrodon 150g, Fructus Lycii 50g, 8 of Scolopendras, Squama Manis 85g, Herba Hedyotidis Diffusae 40g, Radix Astragali 100g, Cordyceps 20g, Cortex Eucommiae 40g, Herba Lysimachiae 30g, Rhizoma Chuanxiong 20g, Radix Aconiti 10g, Olibanum 10g, Myrrha 10g, Moschus 1g, Rhizoma Sparganii 10g, Rhizoma Curcumae 10g, Radix Polygalae fallacis 3g, Herba Artemisiae annuae 3.5g, Herba clerodendranthi spicati 4g and Fols Picridis fuscipilosae 12g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410383151.XA CN104189732A (en) | 2014-08-06 | 2014-08-06 | Traditional Chinese medicine composition for treating osteosarcoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410383151.XA CN104189732A (en) | 2014-08-06 | 2014-08-06 | Traditional Chinese medicine composition for treating osteosarcoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104189732A true CN104189732A (en) | 2014-12-10 |
Family
ID=52075203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410383151.XA Pending CN104189732A (en) | 2014-08-06 | 2014-08-06 | Traditional Chinese medicine composition for treating osteosarcoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104189732A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721305A (en) * | 2018-05-28 | 2018-11-02 | 南京工业大学 | Application of the β-elemonic acid in preparing anti-human bone and flesh tumor medicine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411854A (en) * | 2007-10-16 | 2009-04-22 | 彭丽英 | External use medicament for eliminating cancer, tumor and sore thereof |
-
2014
- 2014-08-06 CN CN201410383151.XA patent/CN104189732A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411854A (en) * | 2007-10-16 | 2009-04-22 | 彭丽英 | External use medicament for eliminating cancer, tumor and sore thereof |
Non-Patent Citations (4)
| Title |
|---|
| 李士怡等: "莪术三棱白花蛇舌草对肿瘤细胞抑制作用的研究", 《实用中医内科杂志》 * |
| 梁良等: "蕲蛇组织提取物抗肿瘤活性的初步探讨", 《大连民族学院学报》 * |
| 段汝钦: "《体质肿瘤学》", 30 September 2013, 天津科学技术出版社 * |
| 陈亮光等: "《实用防癌大全》", 31 October 1999 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721305A (en) * | 2018-05-28 | 2018-11-02 | 南京工业大学 | Application of the β-elemonic acid in preparing anti-human bone and flesh tumor medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103007216B (en) | Chinese medicinal composition for treating chronic diarrhea | |
| CN103585299B (en) | Medicine for treating disc protrusion and bulge of lumbar vertebra and cervical vertebra | |
| CN103230561B (en) | Traditional Chinese medicine for treating frequent urination caused by deficiency of kidneys | |
| CN103211932B (en) | Traditional Chinese medicine composition for treating rheumatism | |
| CN104606582A (en) | Traditional Chinese medicine formula for treating anemofrigid-damp arthralgia | |
| CN103110765B (en) | Traditional Chinese medicine for treating renal calculi | |
| CN102441155A (en) | Chinese patent medicine for warming meridians and expelling cold | |
| CN104324340A (en) | Traditional Chinese medicine preparation for treating calcaneal bone hyperplasia and preparation method of traditional Chinese medicine preparation | |
| CN106266896A (en) | A kind of invigorating primordial QI, kidney invigorating and YANG supporting, bone and muscle strengthening, the pill of curing rheumatism | |
| CN103816391A (en) | Traditional Chinese medicinal wine for treating osteomyelitis and preparation method thereof | |
| CN104189732A (en) | Traditional Chinese medicine composition for treating osteosarcoma | |
| CN104189865A (en) | Traditional Chinese medicine preparation for gonitis and preparation method of traditional Chinese medicine preparation | |
| CN101366937A (en) | Chinese medicine for treating colonitis | |
| CN103099879B (en) | Traditional Chinese medicine (TCM) preparation for treating fifth-watch diarrhea | |
| CN103191229B (en) | Traditional Chinese medicine for treating swelling of knee joints | |
| CN104857098A (en) | Traditional Chinese medicine for treating sciatica | |
| CN104096045A (en) | Traditional Chinese medicine composition for treating gouty arthritis | |
| CN105616966A (en) | Traditional Chinese medicine for treating arthritis | |
| CN104189661A (en) | Traditional Chinese medicine for treating fibromyalgia syndrome | |
| CN103751656A (en) | Traditional Chinese medicine decoction for treating turbid urea disease | |
| CN103520569B (en) | Traditional Chinese medicine for treatment of lumbago of syndrome of yin deficiency of liver and kidney | |
| CN105456630A (en) | Traditional Chinese medicine composition for treating pathologic leucorrhea | |
| CN104984032A (en) | Traditional Chinese medicine composition for treating leukorrhagia | |
| CN105663992A (en) | Traditional Chinese medicine composition for treating chronic annexitis | |
| CN105362986A (en) | Traditional Chinese medicine composition for treating rheumatism cold disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141210 |